Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 3 , Pages 334-344 , September 2009

Well-defined and potent liposomal hepatitis B vaccines adjuvanted with lipophilic MDP derivatives

Received 1 June 2008 ,Accepted 24 December 2008.

References 

  1. Perillo RP. Treatment of chronic hepatitis with interferon: experience in western countries. Semin Liver Dis. 1989;9:240–248
  2. Beasley RP, Hwang LY. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis. 1983;147:185–190
  3. Stevens CE, Beasley RP, Tsui J, Lee WE. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292:771–774
  4. Hu JE, Cheng Z, Chisari FV, Vu TH, Hoffman AR, Campbell TC. Repression of hepatitis B virus (HBV) transgene and HBV-induced liver injury by low protein diet. Oncogene. 1997;15:2795–2801
  5. Hoofinagle JH, Bisceglie de AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997;336:347–356
  6. Lai H, Chein CL, Leung RN, Chang TT, Gran R, Tai DI, et al. A one year trial of chronic hepatitis B. Asia hepatitis Lamivudine study group. N Engl J Med. 1998;339:61–68
  7. Michel ML, Loirat D. Vaccines for prophylactic or therapeutic immunization against hepatitis B. Intervirology. 2001;44:78–87
  8. Chen HL, Chang MH, Ni YH, Hsu HY, Lec PI, Lec CY, et al. Seroepidemology of hepatitis B virus infection in children, ten years of mass vaccination in Taiwan. JAMA. 1986;276:906–908
  9. Bramwell VW, Perrie Y. The rational design of vaccines. Drug Discov Today. 2005;10:1527–1534
  10. Bramwell VW, Perrie Y. Particulate delivery systems for vaccines. Crit Rev Ther Drug Carrier Syst. 2005;22:151–214
  11. Merser CP, Sinay P, Adam A. Total synthesis and adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1975;66:1316–1322
  12. Nagao S, Tanaka A, Yamamoto Y, Koga T, Onoue K, Shiba T, et al. Inhibition of macrophage migration by muramyl dipeptide. Infect Immun. 1979;24:308–312
  13. Neter E. Endotoxin and the immune response. Curr Top Microbiol Immunol. 1969;47:82–124
  14. Tanaka A, Nagao S, Nagao R, Kotani S, Shiba T, Kusumoto S. Stimulation of reticuloendothelial system of mice by muramyl dipeptide. Infect Immun. 1979;24:302–307
  15. Waters RV, Ferrarest RW. Muramyl dipeptide stimulation of particle clearance in several animal species. J Reticuloendothelial Soc. 1980;28:308–312
  16. Taniyama T, Holden HT. Direct augmentation of cytolytic activity of tumor-derived macrophages and macrophage cell lines by muramyl dipeptide. Cell Immunol. 1979;48:369–374
  17. Wahl SM, Wahi LM, Mccarthy JB, Chedid L, Mergenhagan SE. Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. J Immunol. 1979;122:2226–2231
  18. Schumann G, Van Hoogevest P, Frankhauser P, Probast A, Peil A, Court M, et al. In:  Lopez-Berstein G,  Fidler IJ editor. Liposomes in the therapy of infectious dieases and cancer. New York: Liss; 1989;p. 191–203
  19. Phillips NC, Moras ML, Chedid L, Lefrancier P, Bernard JM. Activation of alveolar macrophages tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. Cancer Res. 1985;45:128–134
  20. Girdin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. Nod2 general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003;278:8869–8872
  21. Kirby C, Gregoriadis G. Dehydration-rehydration vesicles (DRV): a new method for high yield drug entrapment in liposomes. Biotechnology. 1984;2:979–981
  22. Vangala A, Bramwell VW, Mcnell S, Christensen D, Agger ME, Perrie Y. Comparison of vesicles based antigen delivery systems for delivery of hepatitis B surface antigen. J Control Release. 2007;5:1–9
  23. Saiki I, Fidler IJ. Synergism between muramyl dipeptide and gamma interferon for activation of mouse alveolar macrophages. J Immunol. 1985;135:20–22
  24. Fry DW, White JC, Goldman ID. Rapid separation of low molecular weight solutes from liposomes without dilution. Anal Biochem. 1978;90:809–815
  25. Laemmli K. Cleavage of structural protein during the assembly of head of bacteriophage T4. Nature. 1970;227:680–685
  26. Chong-Kook K, Eun JJ. Development of dried liposomes as effective immuno-adjuvant for hepatitis B surface antigen. Int J Pharm. 1995;115:193–199
  27. Julia A, Metcalf JI, Gallin WM, Nausecf RK. In: Lab manual of neutrophil function. NewYork: Paven Press; 1986;p. 113–115
  28. Hwang KJ. Liposome pharmacokinetics. In:  Outro M editors. Liposomes. New York: Marcel Dekker; 1987;p. 109–156
  29. Saraf S, Mishra D, Asthana A, Jain R, Singh S, Jain NK. Lipid microparticles for mucosal immunization against hepatitis B. Vaccine. 2006;24:45–56
  30. Sanior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Sys. 1987;3:123–193
  31. Brynestad K, Babbaitt B, Huang L, Rouse BT. Influence of peptide acylation, liposome incorporation and synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines. J Virol. 1989;64:680–685
  32. Tamawa M, Yoo YC, Yoshimotsa K, Yoshida R, Oka T, Ohkuma K, et al. Effect of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen. Vaccine. 1995;77–82
  33. Nagarsenkar MS, Londhe VY, Nadkanig D. Preparation and evolution of liposomal formulation of tropicamide ocular delivery. Int J Pharm. 1999;190:63–71
  34. Browning JL. Dynamic properties of amine-containing head groups. Biochemistry. 1981;20:7144–7151
  35. Israelachvili JN. Theoretical considerations on the asymmetric distribution of charged phospholipids molecules on the inner and outer layers of curved bilayer membranes. Biochem Biophys Acta. 1973;323:659–663
  36. Roy MT, Gallardo M, Esterlich J. Bilayer distribution of phosphatidylserine and phosphatidylethanolamine in lipid vesicles. Bioconjug Chem. 1997;8:941–951
  37. New RRC. In: Liposomes: a practical approach. London: Oxford OCRL Press; 1981;p. 1–30
  38. Lowy I, Theze J, Chedid L. Stimulation of the in vivo dinitrophenyl antibody response to the DNP conjugate of L-glutamic acid60-l-alanine30-l-tyrosine10 (GAT) polymer by a synthetic adjuvant, muramyl dipeptide (MDP): target cells for adjuvant activity and isotypic pattern of MDP-stimulated response. J Immunol. 1980;124:100–104
  39. Sugimura K, Uemiya M, Saiki I, Azuma I, Yamamura Y. The adjuvant activity of synthetic N-acetylmuramyl-dipeptide: evidence of initial target cells for the adjuvant activity. Cell Immunol. 1979;43:137–149
  40. Moingeon P, Haensler J, Lindberg A. Towards the rational design of Th1 adjuvants. Vaccine. 2001;19:4363–4372
  41. O'Hagan DT, Mackichan ML, Singh M. Recent developments in adjuvants for vaccines against infectious dieases. Biomol Eng. 2001;18:69–85
  42. Babbitt BP, Allen PM, Matsueda G, Haber E, Unanue ER. Binding of immunogenic peptides to la histocompatibility molecules. Nature. 1985;317:359–361
  43. Babbitt BP, Matsueda G, Haber E, Unanue ER, Allen PM. Antigen competition at the label of peptide-la binding. Proc Natl Acad Sci USA. 1986;83:4509–4513
  44. Marrack P. New insights into antigen recognition. Science. 1987;235:1311–1313
  45. Unanue ER, Allen PM. The basis for the immunoregulatory role of macrophages and other accessory cells. Science. 1987;236:551–557
  46. Adam A, Petit JF, Lefrancier P, Lederer E. Muramyl peptides: chemical structure, biological activities and mechanism of action. Mol Cell Biochem. 1981;41:27–42
  47. Rodney JY, Rae Lyn B, Thomas CM. Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs. J Virol. 1989;63:2951–2958
  48. Cunningham AL, Merigan TC. Gamma in interferon production appears to predict time of recurrence of herpes labialis. J Immunol. 1983;130:2397–2400
  49. Torseth JW, Merigan TC. Significance of local gamma interferon in recurrent herpes simplex infection. J Infect Dis. 1986;157:979–984
  50. Sone S, Fidler IJ. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages. J Immunol. 1980;125:2454–2460
  51. Zonneveld GM, Cromellin DJA. Liposomes: parentral administration to man. In:  Gregoriadis G editors. Liposomes as drug carriers. Chichester, UK: John Wiley & Sons Ltd.; 1988;p. 795–817

PII: S1549-9634(09)00004-5

doi: 10.1016/j.nano.2008.12.004

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 3 , Pages 334-344 , September 2009

Article Tools

* Image Usage & Resolution